Valuation
- Market cap
- 1,908,627,000
- Revenue TTM
- $0
- Net income TTM
- $-41,720,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 82,497
- Avg volume
- 202,754
- Day's range
- $129.51 – $133.27
- Shares out
- 14,408,000
- Stochastic %K
- 16%
- Beta
- -0.27
- Analysts
- Strong Sell
- Price target
- $229.19
Company profile
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat...
Show more
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 484 253 1461
- Website
- https://palvellatx.com
- Address
- 353 W. Lancaster Avenue, Suite 200, Wayne, United States
Latest news
No headlines yet.
